Publications by authors named "Eri Yasuda-Imanishi"

Bardoxolone methyl (BX) is expected to be an innovate therapeutic agent for chronic kidney disease (CKD). The aim of the present study was to examine whether the expression of subtypes of cytochrome P450 (CYP) and ABC transporters was altered in human hepatocellular carcinoma HepG2 cells by exposure to BX. The expression of mRNAs for CYP1A2, CYP2E1, P-glycoprotein, multidrug resistance-associated protein 1-3, and breast cancer resistance protein was significantly increased by exposure of HepG2 cells to BX, while the expression of CYP3A4 mRNA was significantly decreased under the same conditions.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Eri Yasuda-Imanishi"

  • - Eri Yasuda-Imanishi's recent research focuses on the effects of bardoxolone methyl (BX) on gene expression related to cytochrome P450 and ABC transporters in human hepatocellular carcinoma HepG2 cells.
  • - The study found that exposure to BX significantly increased the expression of specific CYP subtypes and ABC transporters, while it decreased the expression of CYP3A4 mRNA.
  • - These findings suggest a potential alteration in drug metabolism and resistance mechanisms in liver cancer cells due to BX, highlighting its implications for therapeutic strategies in chronic kidney disease and liver cancer management.